BiotechTube

Felzartamab + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin A Nephropathy (IgAN)

Conditions

Immunoglobulin A Nephropathy (IgAN)

Trial Timeline

May 8, 2025 → Jun 5, 2029

NCT ID
NCT06935357

About Felzartamab + Placebo

Felzartamab + Placebo is a phase 3 stage product being developed by Biogen for Immunoglobulin A Nephropathy (IgAN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06935357. Target conditions include Immunoglobulin A Nephropathy (IgAN).

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT07219043Phase 2Recruiting
NCT06935357Phase 3Recruiting
NCT06685757Phase 3Recruiting
NCT05021484Phase 2Completed

Competing Products

11 competing products in Immunoglobulin A Nephropathy (IgAN)

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
41
zigakibartNovartisPhase 2
52
iptacopanNovartisPhase 3
77
CCX168AmgenPhase 2
51
InebilizumabAmgenPhase 2
51
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
76
rilzabrutinib + GlucocorticoidsSanofiPhase 2
51
FelzartamabBiogenPhase 2
49
SparsentanTravere TherapeuticsPhase 2
47
SparsentanTravere TherapeuticsPhase 2
47
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
72

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82